Pulmatrix Pursues Merger with Cullgen Amid Regulatory Challenges and Strategic Growth Plans

Pulmatrix Advances Merger Plans Amid Regulatory Delays

Pulmatrix, Inc., a biopharmaceutical company specializing in inhaled therapeutic products for migraine and respiratory diseases, is actively navigating the complexities of its merger with Cullgen Inc. The merger awaits approval from the China Securities Regulatory Commission (CSRC), a critical step in solidifying the partnership. Despite initial progress, including stockholder approval in June 2025 and an effective Form S-4 filing in May 2025, the CSRC's pending decision presents a significant hurdle. Interim CEO Peter Ludlum emphasizes the company's commitment to the merger, noting that both parties have agreed to waive the "No Solicitation" clause in their Merger Agreement, allowing for the exploration of alternative transactions during this waiting period.

The merger's completion is contingent on several conditions, including the Nasdaq’s approval for listing Pulmatrix's common stock shares, which will be issued as part of the merger. If finalized, the merger is expected to enhance Pulmatrix's operational capabilities by integrating Cullgen's resources and expertise. This strategic move is vital for Pulmatrix as it looks to expand its product development efforts. The company’s proprietary iSPERSE™ technology underpins its approach to addressing significant unmet medical needs, particularly in the realms of migraine and respiratory care, thereby positioning Pulmatrix as a key player in the biopharmaceutical landscape.

As of September 30, 2025, Pulmatrix reports a robust cash and cash equivalents balance of $4.8 million, which is anticipated to sustain its operations through at least the fourth quarter of 2026. This financial stability reflects the company’s ongoing operational efficiencies and strategic focus on optimizing its business position while pursuing the merger with Cullgen. The current developments underscore Pulmatrix's resilience and proactive stance in navigating regulatory challenges while remaining committed to its mission of delivering innovative therapeutic solutions.

In addition to its merger activities, Pulmatrix's ongoing product development initiatives continue to draw attention within the industry. The company’s focus on inhaled therapies positions it well to address the rising demand for non-invasive treatment options in both migraine and respiratory care. With a strong commitment to innovation and strategic growth, Pulmatrix aims to enhance its market presence and drive future success in the biopharmaceutical sector.